Results 41 to 50 of about 1,250,673 (409)

Adjuvant chemotherapy [PDF]

Cancer, 1978
In this brief presentation, an attempt was made to illustrate why it is not possible to carry over chemotherapeutic trial results from one animal cancer to another or one human cancer to another without corrections for differences in (a) staging, (b) dose response, and (c) tumor regrowth rates.
openaire   +2 more sources

Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer

New England Journal of Medicine, 2018
BACKGROUND The recurrence score based on the 21‐gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low; however, there is uncertainty about the benefit of chemotherapy
J. Sparano, R. Gray, D. Makower, K. Pritchard, K. Albain, D. Hayes, C. Geyer, E. Dees, M. Goetz, J. Olson, T. Lively, S. Badve, T. Saphner, L. Wagner, T. Whelan, M. Ellis, S. Paik, W. Wood, P. Ravdin, M. Keane, H. G. Gomez Moreno, P. Reddy, T. Goggins, I. Mayer, A. Brufsky, D. Toppmeyer, V. Kaklamani, J. Berenberg, J. Abrams, G. Sledge   +29 more
semanticscholar   +1 more source

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Journal of Clinical Oncology, 2020
PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for ...
A. Léon-Castillo, S. D. de Boer, M. Powell, L. Mileshkin, H. Mackay, A. Leary, H. Nijman, N. Singh, P. Pollock, P. Bessette, A. Fyles, C. Haie-meder, V. Smit, R. Edmondson, H. Putter, H. Kitchener, E. Crosbie, M. de Bruyn, R. Nout, N. Horeweg, C. Creutzberg, T. Bosse   +21 more
semanticscholar   +1 more source

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer [PDF]

, 2014
Background: HAGE protein is a known immunogenic cancer-specific antigen. Methods: The biological, prognostic and predictive values of HAGE expression was studied using immunohistochemistry in three cohorts of patients with BC (n=2147): early primary (EP ...
A G Pockley, AC Wolff, AJ Linley, C Denkert, C Johnson, C Lurquin, CJ Piyathilake, CW Elston, DR Germain, E Dotan, E Yakirevich, EF Velazquez, G Qu, G R Ball, I O Ellis, J Kim, J Roman-Gomez, J Soares, JP Issa, L Harris, L Yang, L Zheng, L Zitvogel, LM McShane, M Clarke, M Otte, ME Hammond, MG Mathieu, MG Mathieu, MO Riener, N Harbeck, NC Wortham, P M Moseley, Q Chen, R C Rees, R Iggo, S E B McArdle, S Gluck, S Shin, S Y T Chan, SE Pinder, SP Adams, T Kurashige, T M A Abdel-Fatah, TM Abdel-Fatah, TM Abdel-Fatah, V Martelange, YI Kim, YT Chen   +48 more
core   +3 more sources

Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection [PDF]

, 2014
Background/Purpose: A proper adjuvant has a relevant role in vaccine formulations to generate an effective immune response. In this study, total Leishmania antigen (TLA) formulated with Montanide ISA 763 or R848 as adjuvants were evaluated as a first ...
Cargnelutti, Diego Esteban, Celedon, Verónica, Cuello Carrión, Fernando Darío, Garcia Bustos, Maria Fernanda, Morea, Gastón, Salomón, María Cristina, Scodeller, Eduardo   +6 more
core   +1 more source

Chemically Synthesized Alcaligenes Lipid A Shows a Potent and Safe Nasal Vaccine Adjuvant Activity for the Induction of Streptococcus pneumoniae-Specific IgA and Th17 Mediated Protective Immunity

Microorganisms, 2020
Effective and safe vaccine adjuvants are needed to appropriately augment mucosal vaccine effects. Our previous study demonstrated that lipopolysaccharide (LPS) from Peyer’s patch resident Alcaligenes stimulated dendritic cells to promote the production ...
Ken Yoshii, Koji Hosomi, Atsushi Shimoyama, Yunru Wang, Haruki Yamaura, Takahiro Nagatake, Hidehiko Suzuki, Huangwenxian Lan, Hiroshi Kiyono, Koichi Fukase, Jun Kunisawa   +10 more
doaj   +1 more source

Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program

International Journal of Gynecological Cancer, 2022
Background The endometrial cancer molecular classification has been integrated into the 2020 World Health Organization (WHO) diagnostic classification and European treatment guidelines, and provides direction towards more effective and less toxic ...
Rainbo Research, Consortium, Gynecological Cancer   +2 more
semanticscholar   +1 more source

Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®)

Frontiers in Immunology, 2020
The concept of adjuvants or adjuvant systems, used in vaccines, exploit evolutionary relationships associated with how the immune system may initially respond to a foreign antigen or pathogen, thus mimicking natural exposure.
Matthew D. Heath, Matthew D. Heath, Mona O. Mohsen, Mona O. Mohsen, Pieter-Jan de Kam, Thalia L. Carreno Velazquez, Simon J. Hewings, Simon J. Hewings, Matthias F. Kramer, Matthias F. Kramer, Thomas M. Kündig, Martin F. Bachmann, Martin F. Bachmann, Murray A. Skinner, Murray A. Skinner   +14 more
doaj   +1 more source

Endotoxin-Free Stx2B-C-CPE Vaccine and Its Optimized Adjuvant Regimen for Preventing Food Poisoning

Frontiers in Bioscience-Landmark, 2023
Background: Clostridium perfringens and Shiga toxin (Stx)-producing Escherichia coli (STEC) are common causes of food poisoning. We previously demonstrated the efficacy of Stx2B-C-CPE, a fusion protein of the C-terminal region of C.
Koji Hosomi, Atsushi Shimoyama, Atsushi Hinenoya, Noritoshi Hatanaka, Takafumi Noguchi, Hirotaka Ebina, Yoko Tojima, Mari Furuta, Masuo Kondoh, Hiroshi Kiyono, Shinji Yamasaki, Koichi Fukase, Jun Kunisawa   +12 more
doaj   +1 more source

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer [PDF]

, 2015
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC).
Ades, F, Ahmed, R, Asher, R, Beresford, M, De Azambuja, E, Gojis, O, Howell, SJ, Januszewski, A, Lewanski, C, Lythgoe, D, Macpherson, IRJ, Owadally, W, Palmieri, C, Riddle, P, Shah, D, Stanley, B, Yan, K   +16 more
core   +2 more sources